WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

ATC codeATC level nameNew DDDUnitAdm.routeDeadline for objection to temporary codesImplementation in ATC/DDD index
A07AA13rifamycin 0.81)O01.09.20232024
A10BH08teneligliptin20mgOfinal2024
B06AX04mitapivat0.1gO01.09.20232024
C03DA05finerenone20mgOfinal2024
G04BD15vibegron75mgO01.09.20232024
H02CA02 osilodrostat10mgOfinal2024
H05BX06evocalcet2.5mgO01.09.20232024
J01AA13 eravacycline0.14gPfinal2024
J01DC52cefuroxime and beta-lactamase inhibitor0.5 2)gOfinal2024
J01DI04cefiderocol6gPfinal2024
J02AA01amphotericin B210mg 3)P01.09.20232024
J02AC06oteseconazole21mgO01.09.20232024
J04AK08 pretomanid0.2gO01.09.20232024
J05AE11ensitrelvir0.175gO01.09.20232024
J05AH04 laninamivir 0.16gInhal.solutionfinal2024
J05AP13ravidasvir0.2gO01.09.20232024
J05AX10 maribavir0.8gO01.09.20232024
J05AX24 tecovirimat1.2gO01.09.20232024
J05AX28 bulevirtide2mgPfinal2024
J05AX31lenacapavir0.19gO01.09.20232024
J05AX31lenacapavir5.1mgP01.09.20232024
L01EA06asciminib80mgO01.09.20232024
L01EL04orelabrutinib0.15gO01.09.20232024
L01EX21tepotinib0.45gOfinal2024
L04AA03antilymphocyte immunoglobulin (horse)1.05gP01.09.20232024
L04AA51 4) anifrolumab10.7mgPfinal2024
L04AA54pegcetacoplan0.3gP01.09.20232024
L04AC19 satralizumab 4.3mgPfinal2024
L04AC22spesolimab0.95)P01.09.20232024
L04AD03voclosporin47.4mgO01.09.20232024
N02CC08lasmiditan0.1gOfinal2024
N02CD05eptinezumab1.1mgP01.09.20232024
R05DB29gefapixant90mgO01.09.20232024
V03AX04difelikefalin15mcgP01.09.20232024
1) as sodium salt
2) refers to cefuroxime
3) lipid formulations
4) New ATC 5th level to be included in the new ATC 4th level L04AG Monoclonal antibodies in the Index 2024
5) course dose

Last updated: 2023-05-11